Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers.

@article{Drane2009PrimingOC,
  title={Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers.},
  author={Debbie Drane and Eugene Maraskovsky and Rebecca Gibson and Sue E Mitchell and Megan J. Barnden and Alan Moskwa and David Murray Shaw and Barbara A. Gervase and Stephen Andrew Coates and Michael W. Houghton and Russel Basser},
  journal={Human vaccines},
  year={2009},
  volume={5 3},
  pages={
          151-7
        }
}
The disease burden and public health impact of chronic HCV infection continues to be a major problem globally. Current treatment for chronic HCV infection is not effective in all patients and is frequently associated with unacceptable side effects. Clearly a need exists for improved treatments and one such strategy is the use of therapeutic vaccines. Although still not completely understood, emerging data indicate that the generation of CD4(+) and CD8(+) T cells are important for the clearance… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

Ever closer to a prophylactic vaccine for HCV

  • Expert opinion on biological therapy
  • 2013
VIEW 4 EXCERPTS
CITES RESULTS & METHODS
HIGHLY INFLUENCED

Similar Papers

Loading similar papers…